To assess the efficacy and safety of nonsurgical treatment with imiquimod (IMQ) 5% cream in patients with periocular nodular basal cell carcinoma (BCC).
Methods:
Fifteen patients with clinical and histopathological diagnosis of nodular BCC on the eyelid were treated with IMQ 5% cream once daily, 5 days/week for 6 weeks. Three patients had tumor persistence after photodynamic therapy and 1 patient had failed cryotherapy.
Results:
All tumors showed histopathological remission within 3 months of starting IMQ, and sustained clinical remission was documented in each patient after 24–28 months' follow-up. Treatment tolerability was bad in 7 patients with local effects being most problematic, but all symptoms disappeared when treatment ended.
Conclusions:
IMQ therapy is effective for treating periocular BCCs with a cure rate similar to that of surgery. Aesthetic results were rated as excellent. IMQ is a useful alternative to surgery in patients with periocular BCCs when other therapies have failed or are not possible.
Get full access to this article
View all access options for this article.
References
1.
AllaliJ., D'HermiesF., RenardG.Basal cell carcinomas of the eyelids. Ophthalmologica, 219:57–71. 2005.
2.
ChristensonL.J., BorrowmanT.A., VachonC.M., TollefsonM.M., OtleyC.C., WeaverA.L., RoenigkR.K.Increasing incidence of nonmelanoma skin cancers in those younger than 40 years. JAMA, 294:681–690. 2005.
3.
MarksR., StaplesM., GilesG.G.Trends in non-melanoma skin cancer treated in Australia: the second national survey. Int. J. Cancer, 53:585–590. 1993.
4.
BogelundF.S., PhilipsenP.A., GniadeckiR.Factors affecting the recurrence rate of basal cell carcinoma. Acta Derm. Venereol., 87:330–334. 2007.
5.
LevinF., KhalilM., McCormickS.A., Della RoccaD., MaherE., La RoccaR.C.Excision of periocular basal cell carcinoma with stereoscopic microdissection of surgical margins for frozen-section control: report of 200 cases. Arch. Ophthalmol., 127:1011–1015. 2009.
6.
WhitakerD.C., GoldsteinG.D., BirkbyC.S., NeradJ.A.Postoperative techniques for corneal protection in Mohs micrographic surgery. J. Dermatol. Surg. Oncol., 14:951–955. 1994.
7.
BlasiM.A., GiammariaD., BalestrazziE.Immunotherapy with imiquimod 5% cream for eyelid nodular basal cell carcinoma. Am. J. Ophthalmol., 140:1136–1139. 2005.
8.
HuberA., HuberJ.D., SkinnerR.B.Jr., KuwaharaR.T., HaqueR., AmonetteR.A.Topical imiquimod treatment for nodular basal cell carcinomas: an openlabel series. Dermatol. Surg., 30:429–430. 2004.
9.
BeutnerK.R., GeisseJ.K., HelmanD., FoxT.L., GinkelA., OwensM.L.Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. J. Am. Acad. Dermatol., 41:1002–1007. 1999.
10.
ShumackS., RobinsonJ., KossardS., GolitzL., GreenwayH., SchroeterA., AndresK., AmiesM., OwensM.Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma. Arch. Dermatol., 138:1165–1171. 2002.
GeisseJ., CaroL., LindholmJ., GolitzL., StamponeP., OwensM.Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. J. Am. Acad. Dermatol., 50:722–735. 2004.
SchiesslC., WolberC., TauberM., OffnerF., StrohalR.Treatment of all basal cell carcinoma variants including large and high-risk lesions with 5% imiquimod cream: histological and clinical changes, outcome, and follow-up. J. Drugs Dermatol., 6:507–513. 2007.
15.
MargoC., WaltzK.Basal cell carcinoma of the eyelid and periocular skin. Surv. Ophthalmol., 38:169–192. 1993.
16.
SilvermanM.K., KopfA.W., GrinC.M., BartR.S., LevensteinM.J.Recurrence rates of treated basal cell carcinomas. Part 2: curettage-electrodesiccation. J. Dermatol. Surg. Oncol., 17:720–726. 1991.
17.
MalhotraR., HuilgolS.C., HuynhN.T., SelvaD.The Australian Mohs database, part II. Periocular basal cell carcinoma outcome at 5-year follow-up. Ophthalmology, 111:631–636. 2004.
SalascheS.Status of curettage and electrodesiccation in the treatment of primary basal cell carcinoma. J. Am. Acad. Dermatol., 10:285–287. 1984.
23.
Suhge d'AubermontP.C., BennettR.G.Failure of curettage and electrodesiccation for removal of basal cell carcinoma. Arch. Dermatol., 120:1456–1460. 1984.
24.
BermanB.Scientific rationale: combining imiquimod and surgical treatments for basal cell carcinomas. J. Drugs Dermatol., 7,1 Suppl 1:s3–s6. 2008.
25.
VidalD., Matías-GuiuX., AlomarA.Fifty-five basal cell carcinomas treated with topical imiquimod: outcome at 5-year follow-up. Arch. Dermatol., 143:266–268. 2007.
26.
TillmanD.K., CarrollM.T.A 36-month clinical experience of the effectiveness of curettage and imiquimod 5% cream in the treatment of basal cell carcinoma. J. Drugs Dermatol., 7,1 Suppl 1:s7–s14. 2008.
27.
WuJ.K., OhC., StruttonG., SillerG.An open-label, pilot study examining the efficacy of curettage followed by imiquimod 5% cream for the treatment of primary nodular basal cell carcinoma. Australas. J. Dermatol., 47:46–48. 2006.
RhodesL.E., De RieM., EnstromY., GrovesR., MorkenT., GouldenV., WongG.A., GrobJ.J., VarmaS., WolfP.Photodynamic therapy using topical methyl aminolevulinate vs surgery for nodular basal cell carcinoma: results of a multicenter randomized prospective trial. Arch. Dermatol., 140:17–23. 2004.
30.
RhodesL.E., de RieM.A., LeifsdottirR., YuR.C., BachmannI., GouldenV., WongG.A., RichardM.A., AnsteyA., WolfP.Five year follow up of a randomized, prospective trial of topical methyl aminolevulinate photodynamic therapy vs surgery for nodular basal cell carcinoma. Arch. Dermatol., 143:1131–1136. 2007.
31.
RigelD.S., TorresA.M., ElyH.Imiquimod 5% cream following curettage without electrodesiccation for basal cell carcinoma: preliminary report. J. Drugs Dermatol., 7,1 Suppl 1:s15–s16. 2008.
32.
SpencerJ.M.Pilot study of imiquimod 5% cream as adjunctive therapy of curettage and electrodesiccation for nodular basal cell carcinoma. Dermatol. Surg., 32:63–69. 2006.
33.
PengQ., WarloeT., BergK., MoanJ., KongshaugM., GierckskyK.E., NeslandJ.M.5-Aminolevulinic acid-based photodynamic therapy. Clinical research and future challenges. Cancer, 79:2282–2308. 1997.
34.
CaekelberghK., AnnemansL., LambertJ., RoelandtsR.Economic evaluation of methyl aminolaevulinate-based photodynamic therapy in the management of actinic keratosis and basal cell carcinoma. Br. J. Dermatol., 155:784–790. 2006.
35.
KarveS.J., FeldmanS.R., YentzerB.A., PearceD.J., BalkrishnanR.Imiquimod: a review of basal cell carcinoma treatments. J. Drugs Dermatol., 7:1044–1051. 2008.
36.
RoweD.E., CarrollR.J., DoyC.L.Jr.Long term recurrence rates in previously untreated (primary) basal cell carcinoma: implications for patient follow up. J. Derm. Surg. Oncol., 15:315–328. 1989.
